Polycythemia vera secondary prevention: Difference between revisions
Created page with "{{CMG}} {{Polycythemia vera}} ==Overview== '''Primary polycythemia''', often called '''polycythemia vera''' (PCV), polycythemia rubra vera (PRV), or erythremia, occur..." |
Shyam Patel (talk | contribs) No edit summary |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Polycythemia vera}} | {{Polycythemia vera}} | ||
{{CMG}}{{AE}} {{MJK}} {{shyam}} | |||
{{SK}} Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia | |||
==Overview== | ==Overview== | ||
Secondary prevention strategy following polycythemia vera include low dose [[aspirin]]. | |||
==Secondary Prevention== | |||
Secondary prevention strategy following polycythemia vera include low-dose aspirin 81mg daily to decrease the risk of the following complications:<ref name="pmid16462024">{{cite journal| author=Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I| title=Role of polyamines derived from arginine in differentiation and proliferation of human blood cells. | journal=Biol Pharm Bull | year= 2006 | volume= 29 | issue= 2 | pages= 234-9 | pmid=16462024 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16462024 }} </ref> | |||
*[[Cardiovascular]] death | |||
*Non-fatal [[myocardial infarction]] | |||
*Non-fatal [[stroke]] | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 11: | Line 17: | ||
{{Hematological malignancy histology}} | {{Hematological malignancy histology}} | ||
[[ | [[Category:Disease]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
Latest revision as of 04:29, 19 February 2018
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera secondary prevention |
|
Risk calculators and risk factors for Polycythemia vera secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3] Synonyms and keywords: Polycythemia rubra vera (PRV); Erythremia; Primary polycythemia; Osler-Vaquez disease; splenomegalic polycythemia
Overview
Secondary prevention strategy following polycythemia vera include low dose aspirin.
Secondary Prevention
Secondary prevention strategy following polycythemia vera include low-dose aspirin 81mg daily to decrease the risk of the following complications:[1]
- Cardiovascular death
- Non-fatal myocardial infarction
- Non-fatal stroke
References
- ↑ Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I (2006). "Role of polyamines derived from arginine in differentiation and proliferation of human blood cells". Biol Pharm Bull. 29 (2): 234–9. PMID 16462024.